| Literature DB >> 29261641 |
Chaoyue Ji1,2, Shiying Tang1,2, Kunlin Yang1,2, Gengyan Xiong1,2, Dong Fang1,2, Cuijian Zhang1,2, Xuesong Li1,2, Liqun Zhou1,2.
Abstract
BACKGROUND To retrospectively explore the factors influencing Mayo Adhesive Probability (MAP) score in the setting of partial nephrectomy. MATERIAL AND METHODS Data of 93 consecutive patients who underwent laparoscopic and open partial nephrectomy from September 2015 to June 2016 were collected and analyzed retrospectively. Preoperative radiological elements were independently assessed by 2 readers. Ordinal logistic regression analyses were performed to evaluate radiological and clinicopathologic influencing factors of MAP score. RESULTS On univariate analysis, MAP score was associated with male sex, older age, higher body mass index (BMI), history of hypertension and diabetes mellitus, and perirenal fat thickness (posterolateral, lateral, anterior, anterolateral, and medial). On multivariate analysis, only posterolateral perirenal fat thickness (odds ratio [OR]=0.88 [0.82-0.95], p=0.001), medial perirenal fat thickness (OR=0.90 [0.83-0.98], p=0.01), and history of diabetes mellitus (OR=5.42 [1.74-16.86], p=0.004) remained statistically significant. Tumor type (malignant vs. benign) was not statistically different. In patients with renal cell carcinoma (RCC), there was no difference in tumor stage or grade. CONCLUSIONS MAP score is significantly correlated with some preoperative factors such as posterolateral and medial perirenal fat thickness and diabetes mellitus. A new radioclinical scoring system including these patient-specific factors may become a better predictive tool than MAP score alone.Entities:
Mesh:
Year: 2017 PMID: 29261641 PMCID: PMC5747148 DOI: 10.12659/msm.907938
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Measurement of perinephric fat at the level of the renal vein. A – anterior perirenal fat thickness; M – medial perirenal fat thickness; L – lateral perirenal fat thickness; AL – anterolateral perirenal fat thickness; PL – posterolateral perirenal fat thickness.
Patient (n=93) clinicopathologic and radiological characteristics.
| Variables | Summary (n=93) |
|---|---|
| Age (yr) | 54 (19–77) |
| Age <55 yr | 47 (50.5%) |
| Age ≥55 yr | 46 (49.5%) |
| Gender | |
| Male | 61 (65.6) |
| Female | 32 (34.4) |
| Body mass index (BMI, kg/mFt) | 25.1 (15.6–33.9) |
| BMI <25 | 44 (47.3%) |
| 25≤ BMI ≤30 | 40 (43.0%) |
| BMI >30 | 9 (9.7%) |
| Hypertension | |
| Yes | 44 (47.3%) |
| No | 49 (52.7%) |
| Diabetes | |
| Yes | 16 (17.2%) |
| No | 77 (82.8%) |
| Coronary heart disease | |
| Yes | 6 (6.5%) |
| No | 87 (93.5%) |
| Side of the tumor | |
| Left | 49 (52.7%) |
| Right | 44 (47.3%) |
| Tumor size (cm) | 2.5 (0.7–13.0) |
| Tumor type | |
| Renal cell carcinoma | 78 (83.9%) |
| Benign tumor | 15 (16.1%) |
| Tumor stage(n=78) | |
| 1a | 70 (89.7%) |
| 1b | 8 (10.3%) |
| Tumor grade(n=73) | |
| G1 | 49 (67.1%) |
| G2 and G3 | 24 (32.9%) |
| Perirenal fat thickness(mm) | |
| Posterior | 15.1 (0–39.6) |
| Posterolateral | 17.0 (0–46.5) |
| Lateral | 16.1 (0–53.7) |
| Anterior | 8.6 (0–39.1) |
| Anterolateral | 10.4 (0–32.7) |
| Medial | 7.3 (0–31.2) |
| Stranding score | |
| 0 | 61 (65.6%) |
| 2 | 19 (20.4%) |
| 3 | 13 (14.0%) |
| MAP score | |
| 0 | 23 (24.7%) |
| 1 | 29 (31.2%) |
| 2 | 12 (12.9%) |
| 3 | 12 (12.9%) |
| 4 | 13 (14.0%) |
| 5 | 4 (4.3%) |
Continuous variables are listed as the sample median (minimum and maximum) and categorical variables as number of patients (percentage). Tumor stage was only available for renal cell carcinoma patients. Tumor grade was unavailable for 20 patients, including those with benign tumor and some rare types of renal cell carcinoma.
Associations of patients’ characteristics with MAP score.
| Variables | MAP score | ||||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | ||
| Age (yr) | 49 (19–71) | 49 (28–73) | 59 (29–67) | 62.5 (37–77) | 54 (42–74) | 62.5 (51–72) | |
| Gender | |||||||
| Male | 8 (34.8%) | 20 (69.0%) | 9 (75.0%) | 9 (75.0%) | 11 (84.6%) | 4 (100.0%) | |
| Female | 15 (65.2%) | 9 (31.0%) | 3 (25.0%) | 3 (25.0%) | 2 (15.4%) | 0 (0.0%) | |
| Body mass index (BMI, kg/m2) | 22.5 (17.6–30.5) | 25.3 (15.6–31.6) | 25.6 (20.7–28.7) | 26.3 (22.0–28.6) | 26.1 (21.3–33.9) | 26.8 (22.0–31.8) | |
| Hypertension | |||||||
| Yes | 4 (17.4%) | 15 (51.7%) | 8 (66.7%) | 6 (50.0%) | 3 (23.1%) | 1 (25.0%) | |
| No | 19 (82.6%) | 14 (48.3%) | 4 (33.3%) | 6 (50.0%) | 10 (76.9%) | 3 (75.0%) | |
| Diabetes | |||||||
| Yes | 2 (8.7%) | 2 (6.9%) | 0 (0.0%) | 2 (16.7%) | 9 (69.2%) | 1 (25.0%) | |
| No | 21 (91.3%) | 27 (93.1%) | 12 (100.0%) | 10 (83.3%) | 4 (30.8%) | 3 (75.0%) | |
| Coronary heart disease | 0.416 | ||||||
| Yes | 0 (0.0%) | 3 (10.3%) | 1 (8.3%) | 0 (0.0%) | 2 (15.4%) | 0 (0.0%) | |
| No | 23 (100.0%) | 26 (89.7%) | 11 (91.7%) | 12 (100.0%) | 11 (84.6%) | 4 (100.0%) | |
| Tumor type | 0.086 | ||||||
| Renal cell carcinoma | 17 (73.9%) | 24 (82.8%) | 11 (91.7%) | 10 (83.3%) | 12 (92.3%) | 4 (100.0%) | |
| Benign tumor | 6 (26.1%) | 5 (17.2%) | 1 (%8.3) | 2 (16.7%) | 1 (7.7%) | 0 (0.0%) | |
| Tumor size (cm) | 2.5 (1.0–6.2) | 2.7 (1.2–5.0) | 2.2 (1.4–13.0) | 2.3 (0.7–12.5) | 2.5 (1.2–4.2) | 2.3 (1.7–3.7) | 0.864 |
| Side of the tumor | 0.576 | ||||||
| Left | 12 (52.2%) | 17 (58.6%) | 7 (58.3%) | 5 (41.7%) | 6 (46.2%) | 2 (50.0%) | |
| Right | 11 (47.8%) | 12 (41.4%) | 5 (41.7%) | 7 (58.3%) | 7 (53.8%) | 2 (50.0%) | |
| Perirenal fat thickness (mm) | |||||||
| Posterolateral | 7.0 (0–18.7) | 17.6 (3.62–35.7) | 21.9 (3.7–46.5) | 20.1 (9.7–28.6) | 19.6 (8.8–24.6) | 28.1 (18.1–37.0) | |
| Lateral | 5.6 (0–37.7) | 18.2 (0–53.68) | 24.7 (3.7–52.1) | 16.1 (5.52–28.6) | 18.6 (12.9–31.9) | 18.0 (5.4–40.1) | |
| Anterior | 3.3 (0–23.8) | 10.64 (0–21.0) | 9.2 (0–37.2) | 11.9 (0–31.7) | 14.4 (0–39.1) | 12.8 (8.0–17.8) | |
| Anterolateral | 5.0 (0–29.5) | 11.3 (3.2–29.0) | 15.1 (0–21.5) | 8.7 (0–20.7) | 10.9 (2.7–32.7) | 20.8 (7.7–30.9) | |
| Medial | 3.5 (0–19.8) | 9.0 (0–20.0) | 7.4 (0–31.2) | 8.1 (0–14.3) | 9.3 (2.6–22.0) | 15.2 (6.5–26.7) | |
| Tumor stage(n=78) | 0.153 | ||||||
| 1a | 14 (82.4%) | 21 (87.5%) | 10 (90.9%) | 10 (100.0%) | 11 (91.7%) | 4 (100.0%) | |
| 1b | 3 (17.6%) | 3 (12.5%) | 1 (9.1%) | 0 (0.0%) | 1 (8.3%) | 0 (0.0%) | |
| Tumor grade(n=73) | 0.777 | ||||||
| G1 | 8 (66.7%) | 16 (66.7%) | 8 (72.7%) | 7 (70.0%) | 9 (75.0%) | 1 (25.0%) | |
| G2 and G3 | 4 (33.3%) | 8 (33.3%) | 3 (27.3%) | 3 (30.0%) | 3 (25.0%) | 3 (75.0%) | |
MAP – Mayo adhesive probability. Continuous variables are listed as the sample median (minimum and maximum) and categorical variables as number of patients (percentage). Tumor stage was only available for renal cell carcinoma patients. Tumor grade was unavailable for 20 patients, including those with benign tumor and some rare types of renal cell carcinoma.
P value was based on multiple logistic regression analyses as ordinal logistic regression analyses were unfeasible.
Multivariable analysis of influencing factors of MAP score.
| Variables | OR | 95% CI | ||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| Age(yr) | 0.001 | 0.351 | ||
| Gender | <0.001 | 0.315 | ||
| Body mass index (BMI, kg/m2) | 0.001 | 0.225 | ||
| Hypertension | 0.004 | 0.547 | ||
| Diabetes | <0.001 | 5.42 | 1.74–16.86 | |
| Tumor type | 0.086 | 0.983 | ||
| Perirenal fat thickness(mm) | ||||
| Posterolateral | <0.001 | 0.88 | 0.82–0.95 | |
| Lateral | 0.002 | 0.083 | ||
| Anterior | 0.002 | 0.714 | ||
| Anterolateral | 0.002 | 0.926 | ||
| Medial | <0.001 | 0.90 | 0.83–0.98 | |
CI – confidence interval; OR – odds ratio; MAP score – 0 was taken as reference.